



# White matter hyperintensity progression is associated with incident probable dementia or mild cognitive impairment

Adam de Havenon <sup>1</sup>, Kevin N Sheth,<sup>1</sup> Sharon D Yeatts,<sup>2</sup> Tanya N Turan <sup>3</sup>, Shyam Prabhakaran<sup>4</sup>

**To cite:** de Havenon A, Sheth KN, Yeatts SD, *et al.* White matter hyperintensity progression is associated with incident probable dementia or mild cognitive impairment. *Stroke & Vascular Neurology* 2022;7:e001357. doi:10.1136/svn-2021-001357

Received 5 October 2021

Accepted 4 April 2022

Published Online First  
29 April 2022

## ABSTRACT

**Background** White matter hyperintensity (WMH) on brain MRI is associated with developing dementia or mild cognitive impairment (MCI), but WMH progression over time has not been fully investigated as an independent risk factor.

**Methods** We performed a post hoc analysis of the Systolic Blood Pressure Intervention Trial - Memory and Cognition in Decreased Hypertension (SPRINT MIND) trial. The primary outcome was incident probable dementia or MCI (dementia/MCI) before the follow-up MRI at 48 months from enrolment. The primary predictor was WMH progression, defined as the Z score difference between the follow-up and baseline WMH volumes. The secondary predictor was a binary WMH progression threshold ( $\geq 1.4$  mL vs  $< 1.4$  mL).

**Results** Among the 433 included patients, 33 (7.6%) developed dementia/MCI. There were 156 (36.0%) patients who met the WMH progression threshold of  $\geq 1.4$  mL, in whom the rate of dementia/MCI was 12.8% (20/156) vs 4.7% (13/277) of patients with  $< 1.4$  mL WMH progression ( $p=0.002$ ). In multivariable logistic regression, the Z score of WMH progression was associated with dementia/MCI (OR 1.51, 95% CI 1.12 to 2.04,  $p=0.007$ ) as was the WMH progression threshold of  $\geq 1.4$  mL (OR 2.89, 95% CI 1.23 to 6.81,  $p=0.015$ ).

**Conclusions** In this post hoc analysis of SPRINT MIND, WMH progression over 48 months was associated with the development of probable dementia or MCI.

## INTRODUCTION

The burden of white matter hyperintensity (WMH) on brain MRI is associated with future risk of developing dementia or mild cognitive impairment (MCI).<sup>1,2</sup> In the SPRINT MIND and ACCORD MIND trials, intensive blood pressure reduction resulted in less WMH progression over time.<sup>3,4</sup> However, WMH progression over time, as opposed to static burden, has not been fully investigated as an independent risk factor for the development of dementia/MCI.<sup>5</sup>

## METHODS

To assess the hypothesis that increased WMH progression is associated with incident dementia/MCI, we evaluated patients

## Summary box

### What is already known about this subject

- ⇒ The burden of white matter hyperintensity (WMH) on brain MRI is associated with future risk of developing dementia or mild cognitive impairment (MCI).
- ⇒ In the SPRINT MIND and Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes (ACCORD MIND) trials, intensive blood pressure reduction resulted in less WMH progression over time.
- ⇒ However, WMH progression over time, as opposed to static burden, has not been fully investigated as an independent risk factor for the development of dementia/MCI.

### What are the new findings

- ⇒ We performed a post hoc analysis of the SPRINT MIND trial. Among the 433 included patients, 33 (7.6%) developed dementia/MCI during follow-up.
- ⇒ There were 156 (36.0%) patients who met the WMH progression threshold of  $\geq 1.4$  mL, in whom the rate of dementia/MCI was 12.8% (20/156) vs 4.7% (13/277) of patients with  $< 1.4$  mL WMH progression ( $p=0.002$ ).
- ⇒ In multivariable logistic regression, the Z score of WMH progression was associated with dementia/MCI (OR 1.51, 95% CI 1.12 to 2.04,  $p=0.007$ ) as was the WMH progression threshold of  $\geq 1.4$  mL (OR 2.89, 95% CI 1.23 to 6.81,  $p=0.015$ ).

### How might it impact on clinical practice in the foreseeable future?

- ⇒ In this post hoc analysis of SPRINT MIND, WMH progression over 48 months was associated with the development of probable dementia or MCI. Because intensive blood pressure control reduces the progression of WMH, additional research is needed to test interventions that reduce WMH progression.

enrolled in SPRINT MIND who had a baseline and 48-month follow-up MRI. We conformed to Strengthening the Reporting of Observational Studies in Epidemiology guidelines for cohort studies.<sup>6</sup> The primary outcome of our analysis was incident probable dementia or MCI (dementia/MCI) before the follow-up MRI. The rigorous adjudication of dementia/MCI in SPRINT MIND has previously been



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Neurology, Yale University, New Haven, Connecticut, USA

<sup>2</sup>Public Health Sciences, MUSC, Charleston, South Carolina, USA

<sup>3</sup>Neurology, MUSC, Charleston, South Carolina, USA

<sup>4</sup>Neurology, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA

## Correspondence to

Dr Adam de Havenon;  
adam.dehavenon@hsc.utah.edu

**Table 1** Baseline demographics and MRI volumes, stratified by the WMH progression threshold of  $\geq 1.4$  mL vs  $< 1.4$  mL

Variable	Full cohort (N=433)	WMH progression $\geq 1.4$ mL (n=156)	WMH progression $< 1.4$ mL (n=277)	P value*
Age	67.3 $\pm$ 7.8	69.7 $\pm$ 8.0	65.9 $\pm$ 7.3	<0.001
Male sex	272 (62.8%)	90 (57.7%)	182 (65.7%)	0.098
Race/ethnicity				0.730
White	277 (64.0%)	97 (62.2%)	180 (65.0%)	
Black	132 (30.5%)	52 (33.3%)	80 (28.9%)	
Hispanic	20 (4.6%)	6 (3.9%)	14 (5.1%)	
Other	4 (0.9%)	1 (0.6%)	3 (1.1)	
History of cardiovascular disease	50 (11.6%)	25 (16.0%)	25 (9.0%)	0.029
History of diabetes	9 (2.1%)	5 (3.2%)	4 (1.4%)	0.294
History of peripheral vascular disease	24 (5.5%)	7 (4.5%)	17 (6.1%)	0.471
History of atrial fibrillation	29 (6.7%)	10 (6.4%)	19 (6.9%)	0.858
Smoking (n=432)				0.050
Never	197 (45.6%)	59 (37.8%)	138 (50.0%)	
Past	180 (41.7%)	75 (48.1%)	105 (38.0%)	
Current	55 (12.7%)	22 (14.1%)	33 (12.0%)	
Alcoholism	10 (2.3%)	3 (1.9%)	7 (2.5%)	1.000
Vigorous physical activities				0.817
$\leq 1$ /week	219 (50.6%)	82 (52.6%)	137 (49.5%)	
1–4/week	152 (35.1%)	53 (34.0%)	99 (35.7%)	
$\geq 5$ /week	62 (14.3%)	21 (13.4%)	41 (14.8%)	
Aspirin use	217 (50.1%)	85 (54.5%)	132 (47.7%)	0.172
Retired	250 (57.7%)	100 (64.1%)	150 (54.2%)	0.044
Education				0.042
<College or other	250 (57.7%)	101 (64.7%)	149 (53.8%)	
College	69 (16.0%)	17 (10.9%)	52 (18.9%)	
Graduate school	114 (26.3%)	38 (24.4%)	76 (27.4%)	
Randomised to intensive blood pressure reduction	241 (55.7%)	73 (46.8%)	168 (60.7%)	0.005
Baseline WMH volume (mL)	5.8 $\pm$ 7.4	9.7 $\pm$ 9.3	3.6 $\pm$ 4.9	<0.001
Baseline total intracranial volume (mL)	1391 $\pm$ 144	1397 $\pm$ 146	1388 $\pm$ 143	0.558

\*P value shown for comparison between WMH progression stratification and calculated with Student's t-test for interval variables and the  $\chi^2$  or Fisher's exact test for binary variables, depending on frequency; interval variables shown as mean $\pm$ SD and binary variables as n (%). WMH, white matter hyperintensity.


described.<sup>7</sup> We excluded 14 patients who were lost to follow-up more than 90 days before the follow-up MRI. The primary predictor was WMH progression, defined as the difference in millilitres between the follow-up and baseline WMH volumes, which was transformed to a Z score for standardisation.<sup>3</sup> The secondary predictor was a binary WMH progression threshold, which was a concordance probability derived cutpoint of WMH progression ( $\geq 1.4$  mL vs  $< 1.4$  mL, area under the receiver operating curve=0.64). We fit logistic regression models to dementia/MCI, with the predictor of WMH progression standardised as a Z score and a priori adjusted for baseline WMH volume and total intracranial volume. With stepwise backwards selection set at a p value of  $< 0.1$ , we selected additional covariates from table 1, including

patient race, retirement status and randomisation arm. As a sensitivity analysis, we adjusted for baseline WMH volume, total intracranial volume, patient age, race, sex, education and randomisation arm.

## RESULTS

The baseline demographics and their association with WMH progression are shown in table 1.

Among the 433 included patients, 33 (7.6%) developed dementia/MCI by the follow-up MRI. The mean WMH progression was 1.7 $\pm$ 3.4 mL, and those in patients with dementia/MCI versus those without were 4.0 $\pm$ 5.8 vs 1.5 $\pm$ 3.0 mL ( $p < 0.001$ ). There were 156 (36.0%) patients who met the WMH progression threshold of  $\geq 1.4$  mL, in



**Figure 1** (A) An example of the pathway between WMH progression on MRI and dementia/MCI, (B) predicted probability\* of incident dementia/MCI for  $\pm 2$  Z scores of WMH progression. \*Adjusted for baseline WMH volume, total intracranial volume, patient race, retirement status and randomisation arm. MCI, mild cognitive impairment; WMH, white matter hyperintensity.

whom the rate of dementia/MCI was 12.8% (20/156) vs 4.7% (13/277) of patients with WMH progression of  $<1.4$  mL ( $p=0.002$ ). In the multivariable logistic regression model, the standardised Z score of WMH progression was associated with dementia/MCI (OR 1.51, 95% CI 1.12 to 2.04,  $p=0.007$ ) as was the WMH progression threshold of  $\geq 1.4$  mL (OR 2.89, 95% CI 1.23 to 6.81,  $p=0.015$ ). These associations remained significant in the sensitivity analyses (respective ORs 1.43 and 2.62,  $p=0.020$  and 0.030). The predicted probability of incident dementia/MCI across  $\pm 2$  Z scores of WMH progression is shown in figure 1.

## DISCUSSION

In this post hoc analysis of SPRINT MIND, the WMH progression over 48 months was associated with the development of probable dementia or MCI, independent of the baseline WMH volume. While these results are concordant with prior research showing that a high burden of baseline WMH volume is associated with worse cognitive function,<sup>5</sup> the extension of that finding to WMH progression over time is important for two reasons. First, SPRINT MIND showed that intensive blood pressure reduction (target systolic  $<120$  mm Hg) resulted in a 0.58 mL reduction in WMH progression,<sup>3</sup> suggesting that the potentially harmful effects of WMH progression could be mitigated. A key limitation to our analysis is that we were not able to control for all potential confounders,

such as the Apolipoprotein E (APOE) genotype. Unfortunately, the current subgroup analysis does not allow investigation of the interaction between intensive blood pressure reduction and WMH progression on the risk of dementia/MCI due to a high potential for subgroup selection bias. Second, besides blood pressure reduction, there are other interventions with plausible beneficial effect on WMH progression including lipid lowering, antiplatelet therapy and optimisation of other vascular risk factors.<sup>8</sup> The findings in this analysis provide further support for the study of novel approaches to reduce WMH progression as a potential treatment to prevent dementia/MCI.

**Contributors** AdH, KNS, SDY, TNT and SP all made substantial contributions to the conception or design of the work, drafting the work or revising it critically for important intellectual content, gave the final approval of the version to be published and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** AdH has investigator-initiated research support from Regeneron, AMGEN and AMAG pharmaceuticals; KNS reports funding from Biogen, Novartis, Bard, Hyperfine, Astrocyte and Alva Health.

**Patient consent for publication** Not applicable.

**Ethics approval** Institutional review board approval was not required for the deidentified dataset, which is publicly available.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iDs

Adam de Havenon <http://orcid.org/0000-0001-8178-8597>

Tanya N Turan <http://orcid.org/0000-0001-5399-8845>

## REFERENCES

- 1 Au R, Massaro JM, Wolf PA, *et al*. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham heart study. *Arch Neurol* 2006;63:246.
- 2 Gorelick PB, Scuteri A, Black SE, *et al*. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/american stroke association. *Stroke* 2011;42:2672–713.
- 3 SPRINT MIND Investigators for the SPRINT Research Group, Nasrallah IM, Pajewski NM, *et al*. Association of intensive vs standard blood pressure control with cerebral white matter lesions. *JAMA* 2019;322:524–34.
- 4 de Havenon A, Majersik JJ, Tirschwell DL, *et al*. Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics. *Neurology* 2019;92:10.1212/WNL.0000000000007093–75.
- 5 DeBette S, Schilling S, Duperron M-G, *et al*. Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis. *JAMA Neurol* 2019;76:81–94.
- 6 BioLINCC: systolic blood pressure intervention trial (sprint). Available: <https://biolincc.nhlbi.nih.gov/studies/sprint/> [Accessed 6 Jul 2021].
- 7 SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, *et al*. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. *JAMA* 2019;321:553–61.
- 8 de Havenon A, Meyer C, McNally JS, *et al*. Subclinical cerebrovascular disease: epidemiology and treatment. *Curr Atheroscler Rep* 2019;21:39.